M Guan1, Y Chen. 1. Centre of Laboratory Medicine, Hua Shan Hospital, Fudan University, Shanghai, 200040, PR China. ming_guan88@yahoo.com
Abstract
BACKGROUND: The p73 gene is a p53 homologue that induces apoptosis and inhibits cell proliferation. N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice. AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer. METHODS: TAp73 was determined by real time polymerase chain reaction (PCR); DeltaNp73 and DeltaN'p73 were assessed using reverse transcription PCR. western blotting was used to analyse protein expression. p53 mutation was determined by immunohistochemistry. RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples. None of the specimens expressed DeltaN'p73. No significant relation was found between TAp73 expression and clinical parameters. The incidence of positive expression of DeltaNp73 correlated with the Gleason score in prostate carcinomas. Cancer samples with wild-type p53 had significantly higher expression of DeltaNp73 than p53 mutant cancers. CONCLUSION: These data suggest a potential role for DeltaNp73 in prostate cancer progression.
BACKGROUND: The p73 gene is a p53 homologue that induces apoptosis and inhibits cell proliferation. N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice. AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer. METHODS:TAp73 was determined by real time polymerase chain reaction (PCR); DeltaNp73 and DeltaN'p73 were assessed using reverse transcription PCR. western blotting was used to analyse protein expression. p53 mutation was determined by immunohistochemistry. RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples. None of the specimens expressed DeltaN'p73. No significant relation was found between TAp73 expression and clinical parameters. The incidence of positive expression of DeltaNp73 correlated with the Gleason score in prostate carcinomas. Cancer samples with wild-type p53 had significantly higher expression of DeltaNp73 than p53 mutant cancers. CONCLUSION: These data suggest a potential role for DeltaNp73 in prostate cancer progression.
Authors: I Casciano; B Banelli; M Croce; G Allemanni; S Ferrini; G P Tonini; M Ponzoni; M Romani Journal: Cell Death Differ Date: 2002-03 Impact factor: 15.828
Authors: Thorsten Stiewe; Sonja Zimmermann; Andreja Frilling; Helmut Esche; Brigitte M Pützer Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: T J Grob; U Novak; C Maisse; D Barcaroli; A U Lüthi; F Pirnia; B Hügli; H U Graber; V De Laurenzi; M F Fey; G Melino; A Tobler Journal: Cell Death Differ Date: 2001-12 Impact factor: 15.828
Authors: Alex I Zaika; Neda Slade; Susan H Erster; Christine Sansome; Troy W Joseph; Michael Pearl; Eva Chalas; Ute M Moll Journal: J Exp Med Date: 2002-09-16 Impact factor: 14.307
Authors: Y Shao; Y Liu; C Shao; J Hu; X Li; F Li; L Zhang; D Zhao; L Sun; X Zhao; D J Kopecko; D V Kalvakolanu; Y Li; D Q Xu Journal: Cancer Gene Ther Date: 2010-08-13 Impact factor: 5.987
Authors: Z Ousati Ashtiani; M Ayati; M H Modarresi; R Raoofian; B Sabah Goulian; W K Greene; M Heidari Journal: Med Oncol Date: 2008-07-29 Impact factor: 3.064